Healthcare Journey
A lifelong journey for everyone

Health is a universal human aspiration. Yet the reality is that more than half of the world’s population lacks access to adequate healthcare services. Sysmex is committed to making high-quality healthcare accessible by expanding the reach of testing, which serves as the gateway to healthcare and forms the basis for effective treatment. To achieve this, we develop and deploy solutions tailored to local needs and healthcare challenges, while also supporting quality management and human resource development. Through these efforts, we aim to enhance healthcare access and help reduce disparities in healthcare around the world.

Driven by global population growth, aging societies, and increasingly advanced healthcare, demand for medical services continues to grow in both scale and complexity. Since its founding, Sysmex has prioritized quality and productivity in testing. By deploying AI-powered test result analysis systems and automating the entire testing process, we aim to support more accurate diagnoses while enabling medical professionals to focus on high-value tasks, such as in-depth data interpretation and close collaboration with physicians.

Among the many diseases with low treatment satisfaction, one of the most prominent is dementia. With the global aging population, the number of dementia patients is projected to reach 130 million by 2050, accompanied by enormous economic costs. It is now understood that Alzheimer’s disease, which accounts for more than half of all dementia cases, is caused by the accumulation of a misfolded protein called amyloid-β in the brain. Sysmex has developed a reagent that leverages its proprietary high-sensitivity, high-precision technology to measure brain amyloid-β accumulation from a small blood sample.

Recent advances in healthcare include genomic analysis, regenerative and cellular medicine, and robotic-assisted surgical technologies. As the global master distributor of surgical robots developed by Medicaroid Corporation (a joint venture between Sysmex and Kawasaki Heavy Industries), Sysmex is steadily expanding access to these technologies. By the end of fiscal 2024, around 10,000 cumulative surgeries had been supported across Japan and Asia. Going forward, we will among other efforts, quantify advanced surgical techniques and provide educational tools to improve physicians’ skills and knowledge. Through these initiatives, we aim to ensure that patients receive higher-quality surgical care and achieve faster recovery.

Utilizing AI and big data for disease prediction, early detection, and prognosis monitoring is becoming a reality. Sysmex is currently working on disease risk evaluation using test data and life logs, and building prevention and prognosis monitoring systems that facilitate behavioral change in individuals. We aim to help realize personalized healthcare, which is optimized to the individual, empathizing with the universal desire of people to live a long and healthy life.